Hookipa Pharma (NASDAQ:HOOK) Earns “Neutral” Rating from HC Wainwright

HC Wainwright reissued their neutral rating on shares of Hookipa Pharma (NASDAQ:HOOK) in a research note released on Friday, Marketbeat Ratings reports.

Several other equities analysts have also issued reports on the company. Royal Bank of Canada lowered Hookipa Pharma from an “outperform” rating to a “sector perform” rating and cut their price target for the company from $48.00 to $2.00 in a research note on Friday, December 20th. JMP Securities cut their target price on shares of Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 21st.

Hookipa Pharma Price Performance

HOOK stock opened at $2.15 on Friday. The company has a 50 day moving average price of $2.48 and a 200 day moving average price of $4.08. Hookipa Pharma has a fifty-two week low of $1.75 and a fifty-two week high of $10.50. The stock has a market capitalization of $25.92 million, a PE ratio of -0.58 and a beta of 0.71.

Hedge Funds Weigh In On Hookipa Pharma

Institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC raised its position in shares of Hookipa Pharma by 38.4% in the 2nd quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock valued at $179,000 after acquiring an additional 83,800 shares during the period. Ikarian Capital LLC bought a new stake in Hookipa Pharma in the third quarter valued at approximately $228,000. Finally, Acadian Asset Management LLC raised its holdings in Hookipa Pharma by 12.3% in the second quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock worth $586,000 after purchasing an additional 108,844 shares during the period. 63.88% of the stock is currently owned by institutional investors and hedge funds.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.